Andreas Mantoulidis

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Dong-Sung Kim, Lorenz Herdeis, Dorothea Rudolph et al. · Nature · 2023 · 497 citations · Full text

Medicine, Oncology, Pharmacology +17

Drugging an undruggable pocket on KRAS

Dirk Kessler, Michael Gmachl, Andreas Mantoulidis et al. · Proceedings of the National Academy of Sciences · 2019 · 434 citations · Full text

Medicine, Molecular Biology, Oncology +15

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS ^G12C Inhibitor

Joachim Bröker, Alex G. Waterson, Chris A. Smethurst et al. · Journal of Medicinal Chemistry · 2022 · 81 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +16

Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteria

Lukas Junk, Volker M. Schmiedel, Somraj Guha et al. · Nature Communications · 2024 · 47 citations · Full text

Life Sciences, Medicinal Chemistry, Molecular Biology +15

Abstract 1271: <i>In vitro</i> and <i>in vivo</i> characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor

Fabio Savarese, Andreas Gollner, Dorothea Rudolph et al. · Cancer Research · 2021 · 22 citations

Medicine, Oncology, Pharmacology +17